UBS Group’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.4M | Sell |
262,426
-1,102,342
| -81% | -$79.6M | ﹤0.01% | 2612 |
|
|
2026
Q1 | $93M | Buy |
1,364,768
+400,110
| +41% | +$28.3M | 0.01% | 1108 |
|
|
2025
Q4 | $73.3M | Buy |
964,658
+512,449
| +113% | +$37.2M | 0.01% | 1267 |
|
|
2025
Q3 | $27.8M | Sell |
452,209
-126,741
| -22% | -$6.6M | ﹤0.01% | 2214 |
|
|
2025
Q2 | $28.3M | Sell |
578,950
-690,697
| -54% | -$32.8M | ﹤0.01% | 2031 |
|
|
2025
Q1 | $64.7M | Buy |
1,269,647
+198,596
| +19% | +$9.91M | 0.01% | 1244 |
|
|
2024
Q4 | $48.3M | Buy |
1,071,051
+905,980
| +549% | +$38.8M | 0.01% | 1498 |
|
|
2024
Q3 | $6.12M | Buy |
165,071
+28,310
| +21% | +$948K | ﹤0.01% | 2861 |
|
|
2024
Q2 | $4.18M | Sell |
136,761
-88,699
| -39% | -$2.87M | ﹤0.01% | 3042 |
|
|
2024
Q1 | $6.56M | Sell |
225,460
-63,288
| -22% | -$1.77M | ﹤0.01% | 2679 |
|
|
2023
Q4 | $7.96M | Buy |
288,748
+210,883
| +271% | +$4.82M | ﹤0.01% | 2299 |
|
|
2023
Q3 | $1.74M | Sell |
77,865
-14,186
| -15% | -$528K | ﹤0.01% | 3573 |
|
|
2023
Q2 | $3.74M | Buy |
92,051
+15,229
| +20% | +$745K | ﹤0.01% | 2873 |
|
|
2023
Q1 | $3.72M | Sell |
76,822
-32,046
| -29% | -$1.46M | ﹤0.01% | 2807 |
|
|
2022
Q4 | $4.16M | Buy |
108,868
+78,107
| +254% | +$3.25M | ﹤0.01% | 2682 |
|
|
2022
Q3 | $1.54M | Sell |
30,761
-27,031
| -47% | -$1.32M | ﹤0.01% | 3387 |
|
|
2022
Q2 | $2.31M | Sell |
57,792
-84,177
| -59% | -$2.95M | ﹤0.01% | 3034 |
|
|
2022
Q1 | $5.3M | Buy |
141,969
+12,297
| +9% | +$474K | ﹤0.01% | 2485 |
|
|
2021
Q4 | $5.16M | Buy |
129,672
+66,850
| +106% | +$2.56M | ﹤0.01% | 2779 |
|
|
2021
Q3 | $2.34M | Buy |
62,822
+62,729
| +67,451% | +$2.58M | ﹤0.01% | 3446 |
|
|
2021
Q2 | $4K | Sell |
93
-32,879
| -100% | -$1.41M | ﹤0.01% | 8687 |
|
|
2021
Q1 | $1.56M | Buy |
32,972
+32,588
| +8,486% | +$1.94M | ﹤0.01% | 3813 |
|
|
2020
Q4 | $23K | Buy |
384
+90
| +31% | +$5.3K | ﹤0.01% | 6841 |
|
|
2020
Q3 | $14K | Sell |
294
-4,769
| -94% | -$235K | ﹤0.01% | 6592 |
|
|
2020
Q2 | $257K | Sell |
5,063
-66,826
| -93% | -$3.28M | ﹤0.01% | 4624 |
|
|
2020
Q1 | $3.21M | Buy |
71,889
+14,140
| +24% | +$712K | ﹤0.01% | 2312 |
|
|
2019
Q4 | $2.77M | Sell |
57,749
-28,857
| -33% | -$1.23M | ﹤0.01% | 3217 |
|
|
2019
Q3 | $2.93M | Buy |
86,606
+77,339
| +835% | +$3.37M | ﹤0.01% | 2912 |
|
|
2019
Q2 | $417K | Buy |
9,267
+411
| +5% | +$16.2K | ﹤0.01% | 4423 |
|
|
2019
Q1 | $334K | Sell |
8,856
-74,541
| -89% | -$2.5M | ﹤0.01% | 4311 |
|
|
2018
Q4 | $2.86M | Buy |
83,397
+53,298
| +177% | +$1.92M | ﹤0.01% | 2671 |
|
|
2018
Q3 | $1.42M | Buy |
30,099
+18,088
| +151% | +$748K | ﹤0.01% | 3519 |
|
|
2018
Q2 | $405K | Buy |
12,011
+1,713
| +17% | +$53.4K | ﹤0.01% | 4471 |
|
|
2018
Q1 | $279K | Sell |
10,298
-65,565
| -86% | -$1.66M | ﹤0.01% | 4559 |
|
|
2017
Q4 | $1.27M | Buy |
75,863
+12,150
| +19% | +$206K | ﹤0.01% | 3578 |
|
|
2017
Q3 | $1.27M | Buy |
63,713
+36,277
| +132% | +$710K | ﹤0.01% | 3511 |
|
|
2017
Q2 | $503K | Buy |
27,436
+3,123
| +13% | +$42.1K | ﹤0.01% | 4111 |
|
|
2017
Q1 | $239K | Buy |
24,313
+17,968
| +283% | +$217K | ﹤0.01% | 4546 |
|
|
2016
Q4 | $69K | Sell |
6,345
-2,765
| -30% | -$29K | ﹤0.01% | 5576 |
|
|
2016
Q3 | $128K | Buy |
9,110
+592
| +7% | +$4.81K | ﹤0.01% | 4847 |
|
|
2016
Q2 | $60K | Sell |
8,518
-37,487
| -81% | -$275K | ﹤0.01% | 5383 |
|
|
2016
Q1 | $296K | Buy |
46,005
+19,774
| +75% | +$343K | ﹤0.01% | 4190 |
|
|
2015
Q4 | $850K | Buy |
26,231
+16,531
| +170% | +$487K | ﹤0.01% | 3538 |
|
|
2015
Q3 | $259K | Buy |
9,700
+8,769
| +942% | +$375K | ﹤0.01% | 4432 |
|
|
2015
Q2 | $45K | Buy |
931
+21
| +2% | +$1.23K | ﹤0.01% | 6091 |
|
|
2015
Q1 | $55K | Sell |
910
-555
| -38% | -$33.9K | ﹤0.01% | 5948 |
|
|
2014
Q4 | $76K | Buy |
+1,465
| New | +$64.5K | ﹤0.01% | 5986 |
|
Other funds holding PTCT
RI
JT
UBS Group's PTCT Position: Q2 2026 in Review
UBS Group reduced its PTC Therapeutics (PTCT) stake by 81% in Q2 2026, selling an estimated $79.6M and leaving 262,426 shares worth $21.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2612.
UBS Group first reported a position in PTCT in Q4 2014 and has held it in 47 quarters since. The position peaked at $93M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- UBS Group held 262,426 shares of PTC Therapeutics worth $21.4M as of Q2 2026.
- UBS Group sold 1,102,342 PTC Therapeutics shares in Q2 2026, an estimated $79.6M.
- PTC Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2612 holding.
- UBS Group first reported a position in PTC Therapeutics in Q4 2014 and has held it in 47 quarters since.
- UBS Group's PTC Therapeutics position peaked at $93M in Q1 2026.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.